Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Dev Neurosci ; 37(2): 95-104, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25720519

RESUMEN

This study aimed to investigate whether the administration of mononuclear cells derived from human umbilical cord blood cells (UCBCs) could ameliorate hypoxic-ischemic brain injury in a neonatal rat model. The left carotid arteries of 7-day-old rats were ligated, and the rats were then exposed to 8% oxygen for 60 min. Mononuclear cells derived from UCBCs using the Ficoll-Hypaque technique were injected intraperitoneally 6 h after the insult (1.0 × 10(7) cells). Twenty-four hours after the insult, the number of cells positive for the oxidative stress markers 4-hydroxy-2-nonenal and nitrotyrosine, in the dentate gyrus of the hippocampus in the UCBC-treated group, decreased by 36 and 42%, respectively, compared with those in the control group. In addition, the number of cells positive for the apoptosis markers active caspase-3 and apoptosis-inducing factor decreased by 53 and 58%, respectively. The number of activated microglia (ED1-positive cells) was 51% lower in the UCBC group compared with the control group. In a gait analysis performed 2 weeks after the insult, there were no significant differences among the sham-operated, control and UCBC groups. An active avoidance test using a shuttle box the following week also revealed no significant differences among the groups. Neither the volumes of the hippocampi, corpus callosum and cortices nor the numbers of neurons in the hippocampus were different between the UCBC and control groups. In summary, a single intraperitoneal injection of UCBC-derived mononuclear cells 6 h after an ischemic insult was associated with a transient reduction in numbers of apoptosis and oxidative stress marker-positive cells, but it did not induce long-term morphological or functional protection. Repeated administration or a combination treatment may be required to achieve sustained protection.


Asunto(s)
Conducta Animal/fisiología , Sangre Fetal/trasplante , Hipoxia-Isquemia Encefálica , Leucocitos Mononucleares/trasplante , Animales , Animales Recién Nacidos , Modelos Animales de Enfermedad , Humanos , Hipoxia-Isquemia Encefálica/metabolismo , Hipoxia-Isquemia Encefálica/patología , Hipoxia-Isquemia Encefálica/terapia , Inyecciones Intraperitoneales , Ratas , Ratas Wistar
2.
Free Radic Biol Med ; 69: 324-30, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24509162

RESUMEN

Molecular hydrogen (H2) scavenges hydroxyl radicals. Recently, H2 has been reported to prevent a variety of diseases associated with oxidative stress in model systems and in humans. Here, we studied the effects of H2 on rat fetal hippocampal damage caused by ischemia and reperfusion (IR) on day 16 of pregnancy with the transient occlusion of the bilateral utero-ovarian arteries. Starting 2 days before the operation, we provided the mothers with hydrogen-saturated water ad libitum until vaginal delivery. We observed a significant increase in the concentration of H2 in the placenta after the oral administration of hydrogen-saturated water to the mothers, with less placental oxidative damage after IR in the presence of H2. Neonatal growth retardation was observed in the IR group, which was alleviated by the H2 administration. We analyzed the neuronal cell damage in the CA1 and CA3 areas of the hippocampus at day 7 after birth by immunohistochemical analysis of the 8-oxo-7,8-dihydro-2׳-deoxyguanosine- and 4-hydroxy-2-nonenal-modified proteins. Both oxidative stress markers were significantly increased in the IR group, which was again ameliorated by the H2 intake. Last, 8-week-old rats were subjected to a Morris water maze test. Maternal H2 administration improved the reference memory of the offspring to the sham level after IR injury during pregnancy. Overall, the present results support the idea that maternal H2 intake helps prevent the hippocampal impairment of offspring induced by IR during pregnancy.


Asunto(s)
Hipocampo/efectos de los fármacos , Hidrógeno/administración & dosificación , Relaciones Materno-Fetales/efectos de los fármacos , Daño por Reperfusión/tratamiento farmacológico , Animales , Femenino , Hipocampo/lesiones , Hipocampo/patología , Humanos , Recién Nacido , Peroxidación de Lípido/efectos de los fármacos , Oxidación-Reducción , Estrés Oxidativo/efectos de los fármacos , Embarazo , Ratas , Daño por Reperfusión/patología
3.
Early Hum Dev ; 89(5): 283-8, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23153570

RESUMEN

Dexamethasone (DEX), a synthetic glucocorticoid, has been widely used to prevent the development of a variety of poor health conditions in premature infants including chronic lung disease, inflammation, circulatory failure, and shock. Although there are some reports of neurologic complications related to DEX exposure, its full effects on the premature brain have not been examined in detail. To investigate the effects of DEX on neural development, we first administered low doses (0.2 mg/kg bodyweight or less) of the glucocorticoid to neonatal rats on a daily basis during the first postnatal week and examined subsequent behavioral alterations at the juvenile stage. DEX-treated rats exhibited not only a significant reduction in both somatic and brain weights but also learning disabilities as revealed in the shuttle avoidance test. The hippocampi of DEX-treated rats displayed a high apoptotic and a low mitotic cell density compared to control rats on day 7 after birth. In a subsequent experiment, neural stem/progenitor cells were cultured in the presence of DEX for 6 days. The glucocorticoid inhibited cell growth without an increase in cell death. These results suggest that administration of DEX to premature infants induces neurological dysfunction via inhibition of the proliferation of neural stem/progenitor cells.


Asunto(s)
Dexametasona/efectos adversos , Hipocampo/efectos de los fármacos , Enfermedades del Sistema Nervioso/inducido químicamente , Enfermedades del Sistema Nervioso/patología , Células-Madre Neurales/efectos de los fármacos , Tamaño de los Órganos/efectos de los fármacos , Análisis de Varianza , Animales , Animales Recién Nacidos , Reacción de Prevención/efectos de los fármacos , Dexametasona/administración & dosificación , Relación Dosis-Respuesta a Droga , Hipocampo/citología , Hipocampo/patología , Inmunohistoquímica , Ratas , Grabación en Video
4.
Pediatr Res ; 70(1): 21-4, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21436760

RESUMEN

Fetal growth restriction (FGR) remains a cause of perinatal brain injury, sometimes leading to neurological and intellectual impairment. Although the mechanisms and pathophysiology of CNS injuries have not been elucidated completely, it is possible carbohydrate and energy metabolism may have an important role in the FGR brain. In this study, FGR was induced in rats by administration of synthetic thromboxane A2 (STA2). Pups were delivered by cesarean section. After killing, samples were obtained from the fetuses of both control and FGR rats for evaluation of carbohydrate and energy metabolism in brain tissue. Lactate and pyruvate levels in brain were reduced significantly in the FGR group. Glucose content in brain tissue tended to be increased in the FGR group. In contrast, glycogen content in brain tissue tended to be lower in the FGR group. However, these differences in glucose and glycogen content did not reach statistical significance. Brain high-energy reserves, including ATP, ADP, AMP, and phosphocreatine (P-Cr), were similar in the control and FGR groups. Gluconeogenesis compensated for chronic fetal hypoxia and decreased glycogen storage. Energy metabolism in the FGR brain is likely to be disrupted as a consequence of lower reserves of energy substrates.


Asunto(s)
Encéfalo/metabolismo , Metabolismo de los Hidratos de Carbono , Metabolismo Energético , Retardo del Crecimiento Fetal/metabolismo , Hipoxia Fetal/metabolismo , Tromboxano A2 , Animales , Encéfalo/patología , Cesárea , Modelos Animales de Enfermedad , Femenino , Retardo del Crecimiento Fetal/inducido químicamente , Retardo del Crecimiento Fetal/patología , Hipoxia Fetal/inducido químicamente , Hipoxia Fetal/patología , Peso Fetal , Edad Gestacional , Gluconeogénesis , Tamaño de los Órganos , Circulación Placentaria , Embarazo , Ratas , Ratas Sprague-Dawley
5.
Exp Neurol ; 219(1): 81-92, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19393646

RESUMEN

Fetal growth retardation (FGR) is a critical problem in the neonatal period, because a substantial population of infants born with FGR go on to develop various developmental disorders. In the present study, we produced FGR model rats by continuous administration of a synthetic thromboxane A2 analogue (STA2) to pregnant rats. The FGR pups exhibited a significant delay in postnatal neurological development. Moreover, behavioral analyses revealed the presence of a learning disability in juvenile FGR male rats. To investigate the mechanism underlying the neurological disorders, histological and biochemical analyses of the brain of FGR rats were performed. The density of neurons in the cortical plate of an FGR brain was low compared with the brains of a similarly aged, healthy rat. Consistent with this finding, the density of TUNEL-positive cells was higher in the cortical plate of FGR brains. Western blot analyses showed that the levels of three brain-specific chondroitin sulfate proteoglycans (CSPGs), neurocan, phosphacan, and neuroglycan C, were all significantly reduced in the brain of neonatal FGR rats compared with those of the control. The reduction of CSPG-levels and morphological changes in the brain may be relevant to neurological dysfunction in FGR.


Asunto(s)
Encéfalo/crecimiento & desarrollo , Encéfalo/metabolismo , Discapacidades del Desarrollo/metabolismo , Retardo del Crecimiento Fetal/metabolismo , Proteoglicanos/deficiencia , Animales , Animales Recién Nacidos , Encéfalo/patología , Recuento de Células , Corteza Cerebral/crecimiento & desarrollo , Corteza Cerebral/metabolismo , Corteza Cerebral/patología , Proteoglicanos Tipo Condroitín Sulfato/metabolismo , Discapacidades del Desarrollo/etiología , Discapacidades del Desarrollo/fisiopatología , Modelos Animales de Enfermedad , Femenino , Retardo del Crecimiento Fetal/inducido químicamente , Retardo del Crecimiento Fetal/fisiopatología , Inhibidores de Crecimiento/toxicidad , Humanos , Recién Nacido , Discapacidades para el Aprendizaje/etiología , Discapacidades para el Aprendizaje/metabolismo , Discapacidades para el Aprendizaje/fisiopatología , Masculino , Proteínas de la Membrana/metabolismo , Neurocano , Embarazo , Proteoglicanos/metabolismo , Ratas , Ratas Sprague-Dawley , Proteínas Tirosina Fosfatasas Clase 5 Similares a Receptores/metabolismo , Tromboxano A2/análogos & derivados , Tromboxano A2/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA